Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities.
Key Corporate Details Incorporated 1998
Acrux is listed on the Australian Stock Exchange (ASX) ASX Code: ACR
ABN: 72 082 001 152
Registered Office and Principal Business Address: 103-113 Stanley Street, West Melbourne, Victoria, 3003, Australia Telephone: +61 3837 90100
Website: www.acrux.com.au
Ross Dobinson - Chair and Non-Executive Director Michael Kotsanis - Managing Director and Chief Executive Officer Geoff Brooke - Non-Executive Director Don Brumley - Non-Executive Director, Chair Audit and Risk Committee Tim Oldham - Non-Executive Director, Chair Human Capital and Nominations Committee
Felicia Colagrande - Product Development and Technical Affairs Director Mark Hyman - Project and Technical Director Joanna Johnson - Company Secretary and Chief Financial Officer
103-113 Stanley Street West Melbourne VIC 3003 Australia Email: investor@acrux.com.au
MUFG Corporate Markets Level 13, Tower 4, 727 Collins Street, Docklands, Victoria, 3008, Australia
Telephone: +61 1300 554 474 (toll free within Australia) Email: support@cm.mpms.mufg.com Web: mpms.mufg.comOpens in new window
Details regarding date and location of AGM, as well as business to be dealt with, to be included in Notice of Meeting, announced to ASX and sent to shareholders at least 28 days prior to the meeting.
